Literature DB >> 10908720

Interaction of viper venom serine peptidases with thrombin receptors on human platelets.

B F Santos1, S M Serrano, A Kuliopulos, S Niewiarowski.   

Abstract

The serine peptidases, thrombocytin and PA-BJ, isolated from the venom of Bothrops atrox and Bothrops jararaca, respectively, induce platelet aggregation and granule secretion without clotting fibrinogen. The specific platelet aggregation activity of each enzyme was about 15 times lower than that of thrombin. This activity was blocked by monoclonal antibodies recognizing protease activated receptor 1 (PAR1) and by heparin, but not by hirudin nor thrombomodulin. Both enzymes induced calcium mobilization in platelets and desensitized platelets to the action of thrombin and the SFLLRN peptide. We compared the effect of thrombin, PA-BJ, and thrombocytin on the degradation of the soluble N-terminal domain of the PAR1 receptor. The major cleavage site by thrombin and both viper enzymes was Arg41-Ser42. In addition, a rapid cleavage of the peptide bond at Arg46-Asn47 by the viper enzymes was observed, resulting in the inactivation of the tethered ligand. PA-BJ and thrombocytin both cleaved at 41-42 and 46-47 peptide bonds, and fragment 42-103 disappeared rapidly. Both viper enzymes caused calcium mobilization in fibroblasts transfected with PAR4 and desensitized these cells to the thrombin action. In conclusion, both PAR1 and PAR4 mediate the effect of viper venom serine peptidases on platelets.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10908720     DOI: 10.1016/s0014-5793(00)01803-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  7 in total

Review 1.  Matrix metalloproteases and PAR1 activation.

Authors:  Karyn M Austin; Lidija Covic; Athan Kuliopulos
Journal:  Blood       Date:  2012-10-18       Impact factor: 22.113

2.  Rapid purification and procoagulant and platelet aggregating activities of Rhombeobin: a thrombin-like/gyroxin-like enzyme from Lachesis muta rhombeata snake venom.

Authors:  Frank Denis Torres-Huaco; Cláudio C Werneck; Cristina Pontes Vicente; Talita Vassequi-Silva; Ana Cláudia Coelho Nery-Diez; Camila B Mendes; Edson Antunes; Sérgio Marangoni; Daniela C S Damico
Journal:  Biomed Res Int       Date:  2013-08-24       Impact factor: 3.411

3.  LCTX-F2, a Novel Potentiator of Coagulation Factors From the Spider Venom of Lycosa singoriensis.

Authors:  Pengpeng Li; Zhongzhe Zhang; Qiong Liao; Er Meng; James Mwangi; Ren Lai; Mingqiang Rong
Journal:  Front Pharmacol       Date:  2020-06-16       Impact factor: 5.810

4.  Acanthocytosis and brain damage in area postrema and choroid plexus: Description of novel signs of Loxosceles apachea envenomation in rats.

Authors:  Luis Fernando Plenge-Tellechea; Ángel Daniel Hernández-Ramos; Juan Manuel Muñoz; Guillermo Barraza-Garza; Edna Rico-Escobar; David Meléndez-Martínez
Journal:  PLoS One       Date:  2019-02-07       Impact factor: 3.240

Review 5.  The Urgent Need to Develop Novel Strategies for the Diagnosis and Treatment of Snakebites.

Authors:  Harry F Williams; Harry J Layfield; Thomas Vallance; Ketan Patel; Andrew B Bicknell; Steven A Trim; Sakthivel Vaiyapuri
Journal:  Toxins (Basel)       Date:  2019-06-20       Impact factor: 4.546

6.  Purification and characterization of BmooAi: a new toxin from Bothrops moojeni snake venom that inhibits platelet aggregation.

Authors:  Mayara Ribeiro de Queiroz; Carla Cristine N Mamede; Nadia Cristina G de Morais; Kelly Cortes Fonseca; Bruna Barbosa de Sousa; Thaís M Migliorini; Déborah Fernanda C Pereira; Leonilda Stanziola; Leonardo A Calderon; Rodrigo Simões-Silva; Andreimar Martins Soares; Fábio de Oliveira
Journal:  Biomed Res Int       Date:  2014-05-29       Impact factor: 3.411

7.  New Insights on Moojase, a Thrombin-Like Serine Protease from Bothrops moojeni Snake Venom.

Authors:  Fernanda G Amorim; Danilo L Menaldo; Sante E I Carone; Thiago A Silva; Marco A Sartim; Edwin De Pauw; Loic Quinton; Suely V Sampaio
Journal:  Toxins (Basel)       Date:  2018-11-28       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.